GlassScriptPhysician profile
Eric Jason Shiffrin
NPI 1023451259
$5,548.15
in general payments reported to CMS, 2019-2025
37 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $722 · 2021: $607 · 2022: $2,088 · 2023: $318 · 2024: $474 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,914.37 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,400.00 | 2022 | |
| Novo Nordisk INC | $1,118.83 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $488.32 | 2020-2025 | Tepezza, Evenity, Repatha |
| Abbott Laboratories | $461.84 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $413.34 | 2019-2025 | Mounjaro, Jardiance |
| Amarin Pharma, INC. | $323.31 | 2020-2023 | |
| Radius Health, INC. | $113.02 | 2020-2023 | Tymlos |
| Alexion Pharmaceuticals, INC. | $91.76 | 2025 | Strensiq |
| Neurocrine Biosciences, INC. | $89.29 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $86.86 | 2023-2025 | Baqsimi |
| Pfizer INC. | $79.79 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $79.09 | 2021-2023 | Gvoke Hypopen |
| Medtronic, INC. | $65.69 | 2022-2023 | Minimed 780g |
| Abbvie INC. | $64.09 | 2025 | |
| Mannkind Corporation | $52.51 | 2023 | Afrezza |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $43.85 | 2020-2025 | |
| Beta Bionics, INC. | $42.34 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Acerus Pharmaceuticals Corporation | $40.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $38.51 | 2020 | |
| Ascendis Pharma Endocrinology INC | $36.98 | 2023-2025 | Yorvipath |
| Corcept Therapeutics | $36.32 | 2021-2023 | Korlym |
| Esperion Therapeutics, INC. | $34.40 | 2025 | Nexletol |
| Medtronic Minimed, INC. | $32.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.93 | 2020-2023 | Synjardy |
| Tolmar, INC. | $30.01 | 2024-2025 | Jatenzo |
| Dexcom, INC. | $29.33 | 2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $29.31 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $26.15 | 2024 | |
| Averitas Pharma INC. | $24.76 | 2025 | Qutenza |
| Glaxosmithkline, LLC. | $22.87 | 2025 | Arexvy, Shingrix |
| Ultragenyx Pharmaceutical INC. | $22.09 | 2020 | |
| Tandem Diabetes Care, INC. | $21.63 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Grt US Holding, INC. | $17.02 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $16.91 | 2025 | Imcivree |
| Clarus Therapeutics INC. | $16.37 | 2021 | |
| Recordati_rare_diseases_inc. | $15.40 | 2023 | Signifor Lar, Isturisa |
| Vistapharm, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Shiffrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.